Objective: The aim of the present study was to investigate the hepatoprotective effect of Livplus (a polyherbal formulation) against CCl 4 -induced hepatotoxicity in rats. Methods: Hepatotoxicity was induced in rats by i.p. injection of CCl 4 once three days for 14 days. Livplus or Silymarin was administered along with CCl 4 and the biochemical parameters like aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkalinephosphatase (ALP), total bilirubin (TB), direct bilirubin, total protein (TP), gamma-glutamyl transferase (GGT), total cholesterol (TC) and triglycerides (TG) were estimated. Furthermore, biomarkers of oxidative stress such as MDA levels, Glutathione contents, SOD and catalase activity in liver tissue were estimated. Results: Treatment with Livplus significantly reduced the elevated levels of ALT, AST, ALP, bilirubin (direct and total), GGT, TC, TG and increased levels of TP compared to CCl 4 control rats. The treatment with Livplus also showed a significant increase in glutathione contents, SOD and catalase activity and a decrease in MDA levels compared to CCl 4 control rats. Conclusion: The finding of present study indicates that Livplus showed a potential hepatoprotective activity. These results support the traditional use of Livplus in the treatment of liver disorders.
INTRODUCTION
Liver is the most essential organ concerned with the biochemical activities in human body. The most important role is to detoxicate the toxic substances. 1 The management of liver disorders is still a challenge. Therefore, the search for more effective and safer hepatoprotective drugs has continued to be an important area of active research. Since, there is no effective synthetic and conventional drugs are available, it has become a highly essential to search new drugs from herbal origin with little side effects. For a long time, herbal drugs are used for the treatment of liver diseases. 2 At present there are various polyherbal formulations available in the market for the treatment of liver diseases. Livplus is one of the polyherbal formulations (Bacfo Pharmaceuticals India Limited, Noida) that consist of several herbal extracts mentioned in Table 1 . It is used as hepatoprotective, hepato-stimulant and offers a compressive coverage of the treatment of liver diseases. [3] [4] [5] [6] [7] [8] [9] But, this drug has not been proved as hepatoprotective drug in any experimental set up. Therefore, in present study we try to investigate hepatoprotective effect of Livplus against CCL 4 -induced hepatotoxicity in rats.
MATERIALS AND METHODS

Drugs and Chemicals
Livplus was gifted by Bacfo Pharmaceuticals India Ltd., Noida (India). Silymarin was purchased from commercial market. All biochemical kits were purchased from Span Diagnostics Ltd., Surat (India). All other chemicals and reagents used in the study were of analytical grade. methyl cellulose (1 mL/kg of 1 %, w/v, p.o.); Group II: Carbon tetrachloride (1 mL/kg, i.p.); Group III: Silymarine (100 mg/kg, p.o.); Group IV, V and VI: Livplus (100, 200 and 400 mg/kg, p.o. in 1 % w/v of CMC), respectively. Livplus or silymarin was given daily for two weeks of respective groups, while carbon tetrachloride was given simultaneously every 72 h for 14 days except in group I.
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At the end of the experiments, blood samples were collected from the retro orbital plexus of rats under light ether anaesthesia, using glass capillaries. For separation of serum blood was allowed to clot for 15 minutes and it was then centrifuged at 5000 rpm for 20 minutes. The serum was stored at -20°C until further biochemical estimation. Serum was used for analysis of various biochemical parameters including, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphate (ALP), total bilirubin (TB), direct bilirubin, total protein (TP), gamma-glutamyl transferase (GGT), total cholesterol (TC) and triglycerides (TG).
Estimation of biomarkers of oxidative stress
Liver was removed and kept in autoclaved inverted petridis in cold conditions. The tissues were cross chopped with surgical scalpel into fine slices in chilled 0.25 M sucrose, quickly blotted on a filter paper. They were minced and homogenized in 10 mM Tris-HCl buffer, pH 7.4 (10 %w/v) with 25 strokes of tight Teflon pestle of glass homogenizer at a speed of 10,000 ×g at 0˚C using the Remi cooling centrifuge. The clear supernatant obtained was used for assay of lipid peroxidation MDA (malondialdehyde) content, endogenous anti-peroxidative enzymes such as superoxide dismutase (SOD), catalase and GSH (glutathione). Lipid peroxidation or MDA formation ,12 SOD activity, [13 catalase activity 14 and GSH 15 were estimated.
Histopathology
After sacrifice, liver tissue of each group was rapidly dissected out and washed immediately with saline and fixed in 10% phosphate buffered formalin. Paraffin-embedded specimens were cut into 5 μm-thick sections and stained with hematoxylin and eosin (H&E). The sections were examined under the light microscope (Olympus BX10, Tokyo, Japan) for the presence of histopathological changes and photomicrographs (Olympus DP12 camera, Japan) were taken. The observer performing histopathological evaluation was blinded to the animal treatment groups.
Statistical analysis
All of the data are expressed as mean ± SEM. Statistical significance between more than two groups was tested using one-way ANOVA followed by the Bonferroni multiple comparisons test as appropriate using computer based fitting program (Prism, Graphpad 5). The significance level was set at P<0.05 for all tests.
RESULTS
Acute oral toxicity
The oral administration of Livplus in rats up to the dose 2000 mg/kg did not show any sign of toxicity and no mortality for 14 days. It was shown that Livplus was safe up to oral dose of 2000 mg/kg of body weight. The experimental protocol was carried out using 1/20 th (100 mg/kg), 1/10 th (200 mg/kg) and 1/5 th (400 mg/kg) dose based on toxicity study.
Effect of Livplus on AST, ALT and ALP in CCl 4 -induced hepatotoxicity in rats
There was a significant (P < 0.001) increase in the levels of AST, ALT and ALP in CCl 4 control rats as compared to normal control rats. In contrast, the treatment with Livplus at the dose of 100 mg/kg showed a significant (P<0.05) reduction in AST and ALT levels as compared to CCl 4 control rats. However, the treatment with Livplus at the dose of 200 and 400 mg/kg or silymarin (100 mg/kg) showed a greater significant (P<0.001) reduction in AST and ALT levels as compared to CCl 4 control rats ( Figure 1A -B).
The treatment with Livplus (200 mg/kg) showed a significant (P < 0.01) decrease in ALP levels as compared to CCl 4 control rats, while the CCl 4 control rats treated with Livplus (400 mg/kg) or silymarin (100 mg/kg) showed more significant (P<0.001) reduction in ALP levels as compared to CCl 4 control group. However, Livplus (100 mg/kg) treated rats did not show any significant difference in the levels of ALP as compared to CCl 4 control group ( Figure 1C ).
Effect of Livplus on total bilirubin, direct bilirubin and total protein in CCl 4 -induced hepatotoxicity in rats CCl 4 control rats showed a significant (P<0.001) increase in the levels of TB and direct bilirubin in CCl 4 control rats as compared to normal control rats. However, the treatment with Livplus (200 and 400 mg/ kg) showed a significant reduction in TB (P<0.05; P<0.001) and direct bilirubin (P<0.01; P<0.001) levels as compared to CCl 4 control rats. In contrast, the treatment with Livplus (100 mg/kg) did not show any significant change in TB and direct bilirubin levels as compared with CCl 4 control group (Figure 2A-B ).
There was a significant (P<0.001) reduction in the levels of TP in CCl 4 control rats as compared to normal control rats. In contrast, the treatment with Livplus (200 and 400 mg/kg) showed a significant (P< 0.05; P<0.001) increase in TP levels as compared to CCl 4 control rats, but Livplus (100 mg/kg) treated rats did not show any significant alteration in the levels of TP as compared with CCl 4 control group ( Figure 2C ).
Effect of Livplus on total cholesterol, triglycerides and GGT in CCl 4 -induced hepatotoxicity in rats
In CCl 4 control rats, TC and TG levels were significantly (P<0.001) increased when compared to normal control rats. The treatment with Liv- Figure 3A-B) .
CCl 4 control rats showed a significant (P<0.001) increase in GGT level as compared to normal control rats. In contrast, the treatment with Livplus (200 and 400 mg/kg) showed a significant (P<0.01; P<0.001) reduction in GGT levels as compared to CCl 4 control rats, while rats treated with 100 mg/kg did not show any significant difference in the levels of GGT as compared with CCl 4 control group ( Figure 3C ).
Effect of Livplus on SOD, MDA, catalase and GSH in CCl 4 -induced hepatotoxicity in rats
In CCl 4 control group, SOD, catalase and GSH levels were significantly (P<0.001) decreased as compared to normal control rats. In contrast, the treatment with Livplus (100, 200 and 400 mg/kg) showed a significant increase in SOD (P<0. showed a significant (P<0.05; P<0.001) reduction in MDA levels as compared to CCl 4 control rats, but Livplus (100 mg/kg) treated rats did not show any significant reduction in the levels of MDA as compared to CCl 4 control group (Figure 4A-D) .
Histopathological observation
The histological profile of the hepatic tissue of the normal control animals showed a normal lobular architecture. Normal hepatocytes were arranged in single cell cords radiating away from a central vein (A). CCl 4 treated rats showed disturbed liver architecture, exhibiting central lobular necrosis with tiny vacuoles, and fatty infiltrations (B). CCl 4 control rats treated with silymarin and Livplus (400 mg/kg) retained normal hepatic tissue architecture, so received significant protection from CCl 4 -induced hepatic damage (C and F). CCl 4 control rats treated with Livplus (200 mg/ kg) showed minimal inflammatory cellular infiltration, regeneration of hepatocytes around central vein was also observed and almost near normal 
DISCUSSION
Liver is one of the vital organs in animal body and plays a central role in transforming and clearing the chemicals, but it is susceptible to toxicity of several agents including drugs and chemicals. More than 900 drugs have been reported to cause liver injury. 16 Carbon tetrachloride is one of the most commonly used chemical for the screening of hepatoprotective drugs. Therefore, administration of CCl 4 can lead to enzymatic activation, mainly by CYP 2 E 1 , into trichloromethyl free radicals (CCl 3 ) inside the membrane of the endoplasmic reticulum. This is followed by chloromethylation, peroxidation and progressive destruction of the unsaturated fatty acid of the endoplasmic reticulum membrane phospholipids. These methods are known as lipid peroxidation, ultimately it is responsible for functional and structural disruption of hepatocytes. 17 In liver damage, cellular enzymes such as AST, ALT, ALP, bilirubin (direct and total) will escape into the serum resulting in elevation of the their serum concentration. Histology of liver showed disturbed liver architecture, exhibiting central lobular necrosis with tiny vacuoles, and fatty infiltrations. 18 Reduction of glutathione content, SOD activity, catalase activity and increased in lipid peroxidation is a markers for the hepatic damage.
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The treatment with Livplus (200 and 400 mg/kg, p.o.), silymarin (100 mg/kg, p.o.) for 14 days showed a significant protection against CCl 4 -induced liver damage by in virtue of reduction in cellular enzymes like AST, ALT, ALP, bilirubin (direct and total). It's hepatoprotective effect is also confirmed by prevention of histological changes caused by CCl 4. The possible mechanism of action may be associated with inhibition of CYP 2 E 1 activity. In present study, CCl 4 control rats showed a significant increase in MDA levels and a decrease in glutathione content, SOD activity, catalase activity as compared to normal control rats. However, the treatment with Livplus (200 and 400 mg/kg, p.o.) or silymarin (100 mg/ kg, p.o.) showed a significant reduction in MDA levels and an increase in glutathione content, SOD activity and catalase activity as compared to CCl 4 control rats. It was previously reported that administration of CCl 4 caused the decrease in number of hepatocytes which in turn might result into decreased hepatic capacity to synthesize protein and glycogen. But, when Livplus was given along with CCl 4, there was a significant increase in total protein which may be due to the hepatoprotective effect. 22 In previous study, it was also reported that Gamma GT (Gamma-Glutamyl Transpeptidase) was significantly increased in rat intoxicated with CCl 4 in comparison with normal control group. 23 GGT which is present in the membrane of endoplasmic reticulum of the hepatocytes. When it is released extensively from damaged hepatic cell to the bloodstream is considered a good diagnostic profile for hepatic damage. In present study, there was a significant increase in the level of GGT in CCl 4 control group, while Livplus treated animals restored the levels of GGT. Administration of CCl 4 control rats caused a significant increase in TC and TG levels. 24 The treatment with Livplus showed a significant reduction in TC and TG levels. In current study, a comparative histopathological study of the liver from various treatments further supported the hepatoprotective potential.
CONCLUSION
These results showed that Livplus (200 and 400 mg/kg) showed a significant protection in dose dependant manner against experimentally induced hepatotoxicity. The possible mechanism behind the hepatoprotective effect of Livplus might be associated with inhibition of CYP 2 E 1 activity and stimulation of antioxidant defense mechanism against the free radicals generated by CCl 4. Therefore, it was concluded that Livplus has a significant hepatoprotective effect. Our present investigation sup- 
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